GeneDetect.com
Our Products Setup or update your Account Frequently Asked Questions About Our Company How you may contact us Search our Product database or the website Return to GeneDetect.com's homepage Shopping Basket Contents Get a valid online quote Checkout
Latest News  

UPDATED 12 October 2017.

POSTED 12 October 2017. 

Press Release 
GeneDetect® announces extension to its major alliance with leading European Pharmaceutical and Diagnostics Company to perform contract gene expression and biomarker validation assays. GeneDetect to receive additional upfront payment and equity investment.
Friday February 10, 8:00am ET  
Auckland (BUSINESS WIRE) February 10, 2012. GeneDetect (Sarasota, Florida and Auckland, New Zealand), a leading supplier of products and services to academic and government research institutions as well as pharmaceutical and biotechnology companies, announced today that it has entered into a 5 year extension of its major alliance with a leading European Pharmaceutical and Diagnostic company (THE COMPANY)  to perform gene expression and biomarker validation assays. The 5 year extension will last until at least January 2018. GeneDetect will receive an additional upfront payment and equity investment as part of the extended alliance.


POSTED 10 January 2011. 
GeneDetect is pleased to announce the opening of a new facility in Sarasota, Florida. This new facility will allow the company to meet increased customer demand from 2011 onwards. 
GeneDetect announced today the opening of its new headquarters in Sarasota, Florida. From the 10th of January 2011 onwards, GeneDetect has relocated to a larger and newer facility located at 4281 Express Lane, Suite L8299, Sarasota, FL 34249. Older customers will remember our original facility was also located in Sarasota. Please update your records. Our full contact details can be found here: Contact Us.


POSTED 8 September 2007
GeneDetect announces major alliance with leading European Pharmaceutical and Diagnostics Company to perform contract gene expression and biomarker validation assays. GeneDetect to receive upfront payment and equity investment.
GeneDetect announced today that it has entered into a major alliance with a leading European Pharmaceutical and Diagnostic company to perform gene expression and biomarker validation assays. The 4 year contract will last until at least September 2011. GeneDetect will receive an upfront payment and equity investment as part of the alliance.

The popular branded GeneDetect® and GreenStar hyperlabeled gene probe product ranges are used to measure gene expression in tissue samples. "The GeneDetect® and GreenStar hyperlabeled gene probe product ranges are used worldwide everyday by researchers in leading research institutes and companies for this purpose and are widely cited in the literature in leading scientific journals" said GeneDetect Chairman and Chief Executive Officer Dr Paul E Hughes. "It is a natural progression then that we begin to work closely with major Pharmaceutical companies on biomarker validation. While we are focused on this major alliance we will ensure all current customers and projects remain fully supported. However since this major alliance will consume most of our production and screening capacity during this time we will be unable to accept new customers and enquiries and we apologize in advance for any inconvenience this may cause".



POSTED 12 December 2005
Roche Diagnostics GmbH and GeneDetect finalize worldwide licensing agreement.
Dr Paul Hughes, CEO of GeneDetect. "Today I am happy to announce that GeneDetect has negotiated a broad license to the valuable Roche Diagnostics GmbH, Digoxigenin/Digoxin patent portfolio for the detection of nucleic acids. This license will allow GeneDetect to release a range of new products incorporating Digoxigenin/Digoxin. We expect these products to become available early in 2006".   

POSTED 16 January 2005
Track the delivery of your orders from our tracking page.
You can now track the delivery of your orders online, direct from our website. Please track your orders here.

POSTED 9 July 2004
Updated 2004-2005 Catalog available.
Our 2004-2005 catalog is now available for download. Download here.

POSTED 16 September 2003
Registration of GeneDetect®  trademark approved.
Today the US Patent and Trademark Office approved registration of the GeneDetect trademark (Reg. 2765935). "This protects the brand we have developed and enables our customers to more easily identify and differentiate our products in the marketplace" said Dr Paul Hughes, CEO of GeneDetect.

POSTED 25 July 2003
Successful licensing of Syngene "In situ Hybridization" patents completed.
Dr Paul Hughes, CEO of GeneDetect stated, "Today I am pleased to announce that we have successfully completed licensing negotiations with Syngene Limited, Australia. The Syngene "In situ Hybridization" patents licensed include US Patents 5,597,692 and 6,265,156, European Patent 0,175,776, Canadian Patent 1,251,119, Australian Patent 579,631 and Japanese Patent 1,970,487. The terms of the licensing agreement will strengthen our position as "the world's largest selection of gene probes" and will secure an important competitive advantage for GeneDetect which is the ability to supply researchers with our highly sensitive GreenStar hyperlabeled gene probe range for use with in situ hybridization".

POSTED 7 May 2003
Updated 2003 Catalog available.
Our 113 page 2003 catalog is now available for download. Download here.

POSTED 4 April 2003.
GeneDetect announces the opening of its North American headquarters in Florida.
Dr Paul Hughes, CEO of GeneDetect stated, "I am pleased to announce the opening of our North American operations today. I believe having headquarters based in the US will allow us to better pursue the opportunities offered and better service our customers located in the North American market".

POSTED 11 December 2002.
PRESS RELEASE. GeneDetect experiences rapid year-on-year revenue growth. 
GeneDetect has significantly exceeded its Q1-Q3 revenue targets for 2002. On the basis of preliminary consolidated results, worldwide revenue due mainly to Gene Probe sales of its popular GreenStar range have grown some 300 percent as compared to the first three quarters of the previous year. Performance in 2003 is expected to show similar rapid growth with the addition of income generated by the sale of rAVE vectors, riboprobe templates and expansion into custom peptide manufacture.

POSTED 24 September 2002.
New Distributor appointed.
GeneDetect is very pleased to announce the appointment of bioFrontier Technology as exclusive distributors of its product range in Singapore. For full contact details click here.

POSTED 2 September 2002.
NEW Promotion. Receive personal "Amazon.com Gift Certificates" when you order two or more GreenStar DIG, Biotin or FITC  labeled and custom designed probes. Custom probes can be prepared to detect any target gene of interest as long as the gene sequence is known. Click here for further details.

POSTED 5 August 2002.
NEW Product Release: GeneDetectTM rAVETM gene delivery reagents. Express your gene of interest in any cell type in vitro or in vivo. rAVE gene delivery reagents are ideal for functional genomic and gene therapy studies and are produced in consultation with a world-leading academic research group. For more details click here. 

POSTED 17 July 2002. 
New Distributor appointed.
GeneDetect is pleased to announce the appointment of MedPro (website, http://www.medpro-wien.at) as exclusive distributors of its product range in Austria. For full contact details click here.

POSTED 17 July 2002.
GeneDetect reaches agreement with Auckland UniServices Limited to exclusively distribute AAV-2 (rAVETM) gene delivery reagents to its worldwide customer base. 
GeneDetect is pleased to announce today the successful completion of negotiations with Auckland UniServices Limited for the exclusive worldwide distribution rights for AAV-2 gene delivery reagents developed within the University of Auckland by Professor Matthew During a leading expert in gene therapy and gene delivery techniques. Auckland UniServices Limited is a company owned by The University of Auckland and set up to facilitate research, consulting and technology transfer (Website, http://www.uniservices.co.nz). Dr Paul Hughes, CEO of GeneDetect stated, "I am pleased to finalize our negotiations with Auckland UniServices Limited. I hope this will be the first of many such agreements between the two companies. The University of Auckland has many other high quality research reagents that we believe we can effectively promote and distribute to the NZD $16 billion global life sciences market".   

POSTED 1 July 2002
NEW Product Release: GeneDetectTM ONE-STEP custom RNA probe synthesis templates featuring T3/T7 or SP6 OptiScriptTM promoters allow for direct in vitro transcription of optimized 80mer riboprobes to ANY target gene. No more sub-cloning or plasmid preps. Add water to dilute the template and then transcribe your riboprobe using your favorite in vitro transcription kit. For more details click here. 

POSTED 6 May 2002
Updated 2002 Catalog available.
Our 80 page 2002 catalog is now available for download. Download here.

POSTED 2 May 2002
Promotion.
Receive a personal "Amazon.com Gift Certificate" when you order two or more GreenStar DIG, Biotin or FITC  labeled probes. Click here for details.

POSTED 3 March 2002.
Promotion.
Receive up to USD$80 of personal Amazon.com Gift Certificates simply by using a credit card to pay for your order!! Click here for details.

POSTED 14 February 2002.
Commercialize your research reagents and/or technology.
GeneDetect announces its Research commercialization program. Find out all the details.

POSTED 4 February 2002.
Real-time multi-currency pricing is now available for you to try on our website.
Multi-currency invoicing is also now available. Settlement by credit card is currently limited to  US dollars, Euros, Pounds Sterling or Japanese Yen.

POSTED 3 February 2002.
On request we custom designed a decoy for the MeCP2 transcriptional repressor implicated in Rett Syndrome.
Read about this here.  Learn more about Rett Syndrome.

POSTED 25 January 2002.
GET eQUOTES AND MAKE ORDERS IN YOUR OWN CURRENCY:
Understanding the global nature of our customers, we are happy to announce that full multi-currency functionality will be incorporated into our website by the end of February. By selecting your currency from a drop down list you will receive real-time conversion of product prices from USD to your selected currency. This will allow you to generate eQuotes or make orders fully in your own preferred currency. We will also begin invoicing in currencies other than USD to complement these changes. We hope this alleviates some of the issues our non US-based customers have faced in the past.  

POSTED, 1 January 2002 
Promotion:
Earn personal Amazon.com gift certificates when you make a purchase in January. Find out how.

POSTED, 5 Dec 2001 
We are happy to announce that COSMO BIO Co., Ltd will act as our distributors for JAPAN and Jingmei Biotech Co., Ltd as our distributors for CHINA. For contact details click here.

POSTED, 17 Sep 2001
GENEDETECT
Transcription Factor Decoys profiled in "The-Scientist" 

POSTED, 1 June 2001 
Available NOW GreenStar* probes  


Links for other
news stories coming soon. 

  

Copyright © 2000-2017 GeneDetect.com Limited